Effect of Breast Cancer Receptor Subtypes and CSF Cytology Status on Survival of Patients With Leptomeningeal Disease.

IF 2.9 3区医学 Q2 ONCOLOGY

Clinical breast cancer Pub Date : 2024-10-05 DOI:10.1016/j.clbc.2024.09.019

Sujan Niraula, Sugam Gouli, Andrea M Baran, Ruth O'Regan, Haley Tyburski, Huina Zhang, Sara Hardy, Nimish Mohile, Carey K Anders, Ajay Dhakal

{"title":"Effect of Breast Cancer Receptor Subtypes and CSF Cytology Status on Survival of Patients With Leptomeningeal Disease.","authors":"Sujan Niraula, Sugam Gouli, Andrea M Baran, Ruth O'Regan, Haley Tyburski, Huina Zhang, Sara Hardy, Nimish Mohile, Carey K Anders, Ajay Dhakal","doi":"10.1016/j.clbc.2024.09.019","DOIUrl":null,"url":null,"abstract":"Background: It is unclear whether breast cancer (BC) subtypes or CSF cytology results are associated with overall survival (OS) among patients with BC leptomeningeal disease (LMD). This single-institution retrospective study compares OS among BC patients with LMD across various breast cancer subtypes and CSF cytology results.Methodology: The study enrolled BC patients diagnosed with LMD between 2010 and 2023. Breast cancer subtypes were classified as A. ER+/HER2-, HER2+, or triple-negative BC (TNBC); B. HER2+, HER2-Low, HER2-Zero. CSF cytology subtypes included CSF+, CSF-, or CSF not tested (NT). OS was summarized via Kaplan-Meier analysis and compared using log-rank test. Cox models were used for multivariate analyses.Results: Out of 69 patients registered, median OS (95% CI) for ER+/HER2- (n = 33), HER2+ (n = 12) and TNBC (n = 24) subtypes were 8.0 (3.02, 24.8), 5.71 (1.61, not estimated) and 3.2 (1.11, 4.95) months (P = .17). In multivariate analysis, TNBC was associated with worse OS versus ER+/HER2- [Hazard Ratio (HR), 95% CI: 2.64, 1.23-5.80, P = .04]. HER2 subtypes (HER2-Zero, n = 21; HER2-Low, n = 32; HER2+, n = 12) showed no significant differences in OS. Median OS (95% CI) for CSF+ (n = 16), CSF- (n = 18), and CSF NT (n = 35) groups were 3.54 (1.61, 12.72), 13.41 (4.95, 61.93) and 3.28 (1.44, 6.92) months (P = .04). Multivariate analysis showed both CSF+ and CSF NT were associated with shorter OS compared to CSF- group [HR (95% CI) 4.50 (1.75, 12.11) for CSF+ vs. CSF-; 2.91 (1.45, 6.26) for CSF NT vs. CSF-; P = .002].Conclusion: TNBC LMD group was associated with worse OS than ER+/HER2- BC LMD when adjusting for other prognostic factors. CSF- LMD patients had better OS than CSF+ or CSF NT LMD.","PeriodicalId":10197,"journal":{"name":"Clinical breast cancer","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2024-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical breast cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clbc.2024.09.019","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: It is unclear whether breast cancer (BC) subtypes or CSF cytology results are associated with overall survival (OS) among patients with BC leptomeningeal disease (LMD). This single-institution retrospective study compares OS among BC patients with LMD across various breast cancer subtypes and CSF cytology results.

Methodology: The study enrolled BC patients diagnosed with LMD between 2010 and 2023. Breast cancer subtypes were classified as A. ER+/HER2-, HER2+, or triple-negative BC (TNBC); B. HER2+, HER2-Low, HER2-Zero. CSF cytology subtypes included CSF+, CSF-, or CSF not tested (NT). OS was summarized via Kaplan-Meier analysis and compared using log-rank test. Cox models were used for multivariate analyses.

Results: Out of 69 patients registered, median OS (95% CI) for ER+/HER2- (n = 33), HER2+ (n = 12) and TNBC (n = 24) subtypes were 8.0 (3.02, 24.8), 5.71 (1.61, not estimated) and 3.2 (1.11, 4.95) months (P = .17). In multivariate analysis, TNBC was associated with worse OS versus ER+/HER2- [Hazard Ratio (HR), 95% CI: 2.64, 1.23-5.80, P = .04]. HER2 subtypes (HER2-Zero, n = 21; HER2-Low, n = 32; HER2+, n = 12) showed no significant differences in OS. Median OS (95% CI) for CSF+ (n = 16), CSF- (n = 18), and CSF NT (n = 35) groups were 3.54 (1.61, 12.72), 13.41 (4.95, 61.93) and 3.28 (1.44, 6.92) months (P = .04). Multivariate analysis showed both CSF+ and CSF NT were associated with shorter OS compared to CSF- group [HR (95% CI) 4.50 (1.75, 12.11) for CSF+ vs. CSF-; 2.91 (1.45, 6.26) for CSF NT vs. CSF-; P = .002].

Conclusion: TNBC LMD group was associated with worse OS than ER+/HER2- BC LMD when adjusting for other prognostic factors. CSF- LMD patients had better OS than CSF+ or CSF NT LMD.

查看原文本刊更多论文

乳腺癌受体亚型和 CSF 细胞学状态对睑板腺疾病患者存活率的影响

背景：目前尚不清楚乳腺癌（BC）亚型或CSF细胞学结果是否与BC左侧脑膜疾病（LMD）患者的总生存期（OS）有关。这项单一机构的回顾性研究比较了不同乳腺癌亚型和CSF细胞学结果的BC LMD患者的OS：该研究招募了2010年至2023年间确诊为LMD的BC患者。乳腺癌亚型分为：A. ER+/HER2-、HER2+或三阴性BC（TNBC）；B. HER2+、HER2-Low、HER2-Zero。CSF细胞学亚型包括CSF+、CSF-或CSF未检测（NT）。OS 通过 Kaplan-Meier 分析进行总结，并使用对数秩检验进行比较。Cox模型用于多变量分析：在69名登记患者中，ER+/HER2-（33人）、HER2+（12人）和TNBC（24人）亚型的中位OS（95% CI）分别为8.0（3.02，24.8）、5.71（1.61，未估计）和3.2（1.11，4.95）个月（P = .17）。在多变量分析中，与ER+/HER2-相比，TNBC与较差的OS相关[危险比（HR），95% CI：2.64，1.23-5.80，P = .04]。HER2亚型（HER2-零，n = 21；HER2-低，n = 32；HER2+，n = 12）的OS无显著差异。CSF+组（n = 16）、CSF-组（n = 18）和CSF NT组（n = 35）的中位OS（95% CI）分别为3.54（1.61，12.72）、13.41（4.95，61.93）和3.28（1.44，6.92）个月（P = .04）。多变量分析显示，与CSF-组相比，CSF+和CSF NT与较短的OS相关[CSF+ vs. CSF-的HR（95% CI）为4.50（1.75，12.11）；CSF NT vs. CSF-的HR为2.91（1.45，6.26）；P = .002]：结论：在调整其他预后因素后，TNBC LMD组的OS比ER+/HER2 BC LMD组更差。CSF- LMD患者的OS优于CSF+或CSF NT LMD。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical breast cancer 医学-肿瘤学

CiteScore

5.40

自引率

3.20%

发文量

174

审稿时长

48 days

期刊介绍： Clinical Breast Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of breast cancer. Clinical Breast Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of breast cancer. The main emphasis is on recent scientific developments in all areas related to breast cancer. Specific areas of interest include clinical research reports from various therapeutic modalities, cancer genetics, drug sensitivity and resistance, novel imaging, tumor genomics, biomarkers, and chemoprevention strategies.